PT - JOURNAL ARTICLE AU - Ghady Haidar AU - Mounzer Agha AU - Amy Lukanski AU - Kelsey Linstrum AU - Rachel Troyan AU - Andrew Bilderback AU - Scott Rothenberger AU - Deborah K. McMahon AU - Melissa Crandall AU - P. Nathan Enick AU - Michelle Sobolewksi AU - Kevin Collins AU - Marc B. Schwartz AU - Jeffrey M. Dueker AU - Fernanda P. Silveira AU - Mary E. Keebler AU - Abhinav Humar AU - James D. Luketich AU - Matthew R. Morrell AU - Joseph M. Pilewski AU - John F. McDyer AU - Bhanu Pappu AU - Robert L. Ferris AU - Stanley M. Marks AU - Cynthia Klamar-Blain AU - Urvi M. Parikh AU - Amy Heaps AU - Paula L. Kip AU - Alan Wells AU - Tami Minnier AU - Derek Angus AU - John W. Mellors TI - Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis AID - 10.1101/2021.06.28.21259576 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.28.21259576 4099 - http://medrxiv.org/content/early/2021/06/30/2021.06.28.21259576.short 4100 - http://medrxiv.org/content/early/2021/06/30/2021.06.28.21259576.full AB - Objectives Immunocompromised patients were excluded from COVID-19 vaccine clinical trials. The objectives of the study were to measure antibody responses, levels, and neutralization capability after COVID-19 vaccination among immunocompromised patients and compare these variables to those of immunocompetent healthcare workers.Methods This is an interim analysis of an ongoing observational, prospective cohort study which launched on April 14, 2021 across Western Pennsylvania. Participants were healthy healthcare workers (HCW) and immunocompromised patients who had completed their COVID-19 vaccination series. Individuals with a history of COVID-19 were not eligible. Serum was collected to measure for the presence of IgG against the SARS-CoV-2 Spike protein using a semi-quantitative assay; antibody levels were available for comparisons. A quasi-random subset of patients was selected for pseudovirus neutralization assays. Seropositivity with 95% Clopper-Pearson exact confidence intervals and distribution of antibody levels were measured. To identify risk factors for seronegativity, clinical characteristics were univariately compared between antibody reactive and non-reactive individuals within the immunocompromised group.Results 107 HCW and 489 immunocompromised patients were enrolled. Compared to HCWs, seropositivity was significantly lower (p<.001) among immunocompromised patients with Solid organ transplant (SOT), autoimmune, hematological malignancies, and solid tumors (HCW=98.1%; SOT=37.2%; autoimmune=83.8%; hematological malignancies=54.7%; and solid tumor=82.4%, p < 0.05). Over 94% of patients with Human Immunodeficiency Virus were seropositive. Among seropositive patients, antibody levels were much lower among SOT (4.5 [2.1,13.1], p=.020). Neutralization titers tightly correlated with antibody levels (Spearman r = 0.91, p < 0.0001).Conclusion Our findings demonstrate the heterogeneity of the humoral immune response to COVID-19 vaccines based on underlying immunosuppressive condition and highlight an urgent need to optimize and individualize COVID-19 prevention in these patients. These findings also have implications on public health guidance, particularly given revised Centers for Disease Control and Prevention recommendations permitting vaccinated individuals to abandon masking and social distancing in most settings. Future studies are warranted to determine assessment of cellular immunity, longitudinal measurement of immune responses, and the safety and efficacy of revaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number K23AI154546. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Pittsburgh Institutional Review Board (Study ID: 21030056/HCC 21-032) and was granted ethical approval by the UPMC Quality Improvement Review Committee, the ethics, regulatory, and legal oversight body for protecting patient/participant rights, confidentiality, consent (including waiver of consent), and the analysis and dissemination of deidentified data within th UPMC system.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available from this ongoing study.